Frontal neural metabolite changes in schizophrenia and their association with cognitive control: A systematic review.
Frontal neural metabolite changes in schizophrenia and their association with cognitive control: A systematic review.
复制标题
精神分裂症的额神经代谢产物变化及其与认知控制的关联:系统评价。
DOI:
10.1016/j.neubiorev.2021.11.010
复制
发表时间:
2022-01
影响因子:
8.2
通讯作者:
Danielmeier C
中科院分区:
文献类型:
--
作者:
Dixon BJ;Kumar J;Danielmeier C
GABA levels are decreased in medial frontal brain areas of schizophrenia patients. Glutamate levels are lower in medial and lateral frontal areas in chronic patients. Working memory performance is associated with frontal GABA and Glu. Prediction errors are associated Glu and medial frontal GABA. Processing speed correlates with medial frontal GABA levels. A large proportion of patients with schizophrenia exhibit deficits in cognitive control functions including working memory, processing speed and inhibitory control, which have been associated with frontal brain areas. In this systematic review, we investigated differences between chronic schizophrenia patients, first-episode (FEP) patients and healthy control groups in the neurometabolite levels of GABA, glutamate, glutamine and Glx in frontal brain areas. Additionally, we reviewed correlations between cognitive control functions or negative symptoms and these neurometabolite levels. Several studies reported decreased GABA or glutamate concentrations in frontal lobe areas, particularly in chronic schizophrenia patients, while the results were mixed for FEP patients. Working memory performance and prediction errors have been associated with frontal GABA and glutamate levels, and processing speed with frontomedial GABA levels in chronic patients. The relationship between metabolites and negative symptom severity was somewhat inconsistent. Future studies should take the participants' age, medication status or responsivity, disease stage and precise anatomical location of the voxel into account when comparing neurometabolite levels between schizophrenia patients and healthy controls.
登录
查看更多内容
DOI:
10.1038/s41386-021-01132-0
发表时间:
2022-01
期刊:
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
影响因子:
--
作者:
Friedman NP;Robbins TW
通讯作者:
Robbins TW
影响因子:
11
作者:
通讯作者:
--
影响因子:
4.7
作者:
Cadena, Elyse J.;White, David M.;Lahti, Adrienne C.
通讯作者:
Lahti, Adrienne C.
影响因子:
7.6
作者:
Chiappelli, Joshua;Rowland, Laura M.;Hong, L. Elliot
通讯作者:
Hong, L. Elliot
影响因子:
4.7
作者:
Egerton A;Bhachu A;Merritt K;McQueen G;Szulc A;McGuire P
通讯作者:
McGuire P